TY - JOUR AU - Li, Minglun AU - Ping, Gong AU - Plathow, Christian AU - Trinh, Thuy AU - Lipson, Kenneth E. AU - Hauser, Kai AU - Krempien, Robert AU - Debus, Juergen AU - Abdollahi, Amir AU - Huber, Peter E. PY - 2006 DA - 2006/03/24 TI - Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells JO - BMC Cancer SP - 79 VL - 6 IS - 1 AB - Several small receptor tyrosine kinase inhibitors (RTKI) have entered clinical cancer trials alone and in combination with radiotherapy or chemotherapy. The inhibitory spectrum of these compounds is often not restricted to a single target. For example Imatinib/Gleevec (primarily a bcr/abl kinase inhibitor) or SU11248 (mainly a VEGFR inhibitor) are also potent inhibitors of PDGFR and other kinases. We showed previously that PDGF signaling inhibition attenuates radiation-induced lung fibrosis in a mouse model. Here we investigate effects of SU9518, a PDGFR inhibitor combined with ionizing radiation in human primary fibroblasts and endothelial cells in vitro, with a view on utilizing RTKI for antifibrotic therapy. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-6-79 DO - 10.1186/1471-2407-6-79 ID - Li2006 ER -